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ABSTRACT
Can Changes in SR Protein Acetylation Affect Alternative Splicing?
Heather E. Knupp
Cellular phenotype and function is determined by the cellular proteome. Within
the cellular proteome there are processes that have a potential to significantly alter the
composition of the proteome. One such process is called alternative splicing. Splicing is
the removal of introns from a pre-mRNA sequence and the remaining pre-mRNA
sequences, called exons, are combined. Alternative splicing modifies the intron-exon
combination, and can form novel products from the different arrangement of the coding
sequences. This process, due to the high potential for new, possibly unwanted products,
is highly regulated and can occur in a tissue and developmental-specific fashion. The
misreguation of alternative splicing has been documented in many human diseases.
The regulation of alternative splicing involves a complex network of proteins and RNA.
Serine-arginine repeat (SR) proteins are a known family of regulatory proteins that bind
within exons to promote exon inclusion into the mature mRNA transcript. SR protein
activity is regulated by the post-translational modification, phosphorylation. Another
post-translational modification of SR proteins known as acetylation has recently been
identified. The acetylation of lysine residues on proteins can result in changes in
localization, function, and/or structure of modified proteins. The location and function of
this post-translational modification on SR proteins has not been determined. Cellular
acetylation status of the HepG2 cell line was increased by histone deacetylase (HDAC)
inhibition, using the HDAC inhibitors MS-275 and SAHA. RNA from treated cells was
isolated for use with RT-PCR arrays developed by Peter Stoilov. Western blotting was
used to determine efficacy of HDAC inhibitors on total cellular acetylation. The future
goal is to understand how acetylation affects alternative splicing and characterize a new
post-translational modification of SR proteins.
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SPECIFIC AIMS

The function and phenotype of a cell is regulated by the cellular proteome. The
process most likely to significantly alter the composition of the proteome is called
alternative splicing. Splicing is the process in which intronic sequences are removed
from pre-mRNA and the remaining exonic sequences combined. Alternative splicing
modifies the pattern of combined introns and exons to form unique mRNA products.
This process is highly regulated to occur in tissue and developmental-specific manners.
Aberrant splice site selection has also been documented in cancers, cystic fibrosis,
frontotemporal dementia, Parkinsonism, and myotonic dystrophy (1). These conditions
underscore the importance of understanding the regulation of alternative splicing. Much
less is known about the role hormones and environmental factors play in regulation of
alternative splicing in somatic tissues.
Regulation of alternative splicing is achieved by the combination of cis-acting
elements and trans-acting factors. The cis-acting elements are sequences within the
pre-mRNA that can contribute to the strength of a splice site, or be critical in recruiting
trans-acting factors to the pre-mRNA. Classical trans-acting factors are
ribonucleoprotein members of the spliceosome, as well as their accompanying
regulatory proteins, called SR proteins. SR proteins belong to the serine/arginine-rich
(SR) protein family, and have been shown to bind to cis-elements within the pre-mRNA
known as exonic splicing enhancer elements (ESEs), thereby promoting exon inclusion.
Activation and localization of SR proteins is regulated by the post-translational
modification, phosphorylation. Recently, another post-translational modification of SR
ix

proteins was found, called acetylation (2). This novel post-translational modification has
yet to be confirmed and characterized for SR proteins.

Specific Aim #1
Hypothesis
SRp20 is acetylated and this post-translational modification (PTM) plays a
functional role in regulating alternative splicing. The interaction may be direct, with
acetylation altering affinity of SRp20 for the pre-mRNA, or working in tandem with
phosphorylation regulating activity, turnover, and/or degradation of the protein (3).
Alternative splicing may be affected indirectly by the acetylation of histones recruiting
chromatin-adaptors, or by modifying the chromatin structure itself (4).

Determine the role of SRp20 acetylation in alternative splicing
HepG2 cells were treated with histone deacetylase (HDAC) inhibitors and RNA
isolated over several time points. The RNA from HDAC inhibitor treated cells were
compared with DMSO control cells by utilizing reverse-transcriptase polymerase chain
reaction (RT-PCR) splicing array technology developed by Dr. Peter Stoilov. Changes in
alternative splicing were determined by quantifying the amount of transcript isoforms
produced. Upon confirmation of alternative splicing changes in HepG2 cells, primary rat
hepatocytes will be treated with the HDAC inhibitors, Vorinostat (SAHA) and Entinostat
(MS-275), and RNA extracted to evaluate possible splicing effects on metabolic genes.
SRp20 acetylation will be confirmed by immunoprecipitation if significant splice variant

x

changes are documented with HDAC inhibition and RNA analysis with the RT-PCR
arrays. Immunoprecipitated SRp20 protein will be analyzed by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting with an
acetyl-lysine antibody, as well as, an anti-SRp20 antibody as a control.

xi

CHAPTER 1
LITERATURE REVIEW
Introduction
Almost all protein-coding genes have pre-mRNAs that are processed in the
nucleus by removing introns and ligating protein-coding portions, called exons, together
in a mechanism known as splicing. Depending on the gene, exon usage can be
variable, such that multiple transcripts are generated from the same protein-coding
gene. Recent reports estimate that over 90% of genes undergo alternative splicing (5).
The numerous transcripts produced are prime candidates for studies on their regulation,
isoform type, and tissue specificity.
I. Overview of Splicing
The mechanism of splicing involves two SN2-type trans-esterification reactions.
First the phosphodiester bond at the 5ʼ splice site (ss) is attacked by an adenosine 2ʼhydroxyl of the intronic branch point sequence (BPS). This generates a free 5ʼ exon and
an intron lariat-3ʼ exon. Next, the 3ʼ hydroxyl of the 5ʼ exon attacks the phosphodiester
bond of the 3ʼ ss leading to ligation of the exon and excision of the lariat intron (6). The
splicing reaction is possible by the formation of a macromolecular ribonucleoprotein
complex called the spliceosome along the pre-mRNA. The spliceosome is comprised of
five small nuclear ribonucleoprotein particles (snRNPs), U1, U2, U4, U5, and U6, along
with many more splicing associated proteins.
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Assembly of the spliceosome along the pre-mRNA is initiated by the recognition
of the 5ʼ and 3ʼ splice sites by the U1 snRNP and the heterodimeric U2AF, forming the E
complex (Figure 1; (6)). In the E complex, all consensus elements are bound by
proteins; U2AF 65/35 binds the polypyrimidine tract and the 3ʼ splice site, and SR
proteins bind to the exonic splicing enhancer elements (ESEs) and contact U2AF, U1
snRNP, and the branch point. The A complex marks the addition of U2 snRNP to the
pre-mRNA BPS in an ATP-dependent manner. Next, the U4/U6 and U5 tri-snRNP is
added forming the B complex (Figure 2; (6)). The splicesome remains catalytically
inactive until the removal of the U1 and U4 snRNPs forming the B* catalytically active
complex. The first catalytic step takes place forming the C complex, and then the
second catalytic step occurs, after which the spliceosomal components dissociate,
ready to be reassembled on a different pre-mRNA site (6).
The need for many components in spliceosomal complexes may originate from
the features surrounding the splicing process. For one, the reactive groups are
recognized multiple times by RNA or associated proteins to ensure precision of splicing
targets. Many of the interactions between RNA:RNA, protein:protein, and RNA:protein
are weak, but are enhanced by combining several of these weak interactions (7). The
rearrangement of the RNPs during spliceosomal assembly involves dynamic
rearrangement of the molecular components to progress through the splicing reaction.
Each step has a different number of RNPs and proteins associated with it, and these
interactions are dependent on the RNA, elements within the RNA, and upstream
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signaling pathways. Due to the complexity of the process, active spliceosomal
complexes may contain upwards of 100 proteins (6).

II. Types of Alternative Splicing
Alternative splicing is the differential combining of exonic and intronic sequences
within a pre-mRNA transcript. The combination of exons and introns determines what
protein isoform is formed from the mRNA, and contributes to the genetic diversity of a
species. Recent estimates from deep sequencing studies indicate that over 90% of
genes are alternatively spliced (5). The regulation of alternative splicing depends upon
the expression and activity of numerous splicing regulatory factors differentially
expressed in tissues and throughout development. The dysregulation in these
alternative-splicing processes can contribute to pathogenesis, demonstrated in a
growing number of diseases, including cystic fibrosis, frontotemporal dementia,
Parkinsonism, retinitis pigmentosa, spinal muscular atrophy, myotonic dystrophy,
premature aging, and cancer (8).
There are five general ways in which alternative splicing can change the
sequence of mRNA (Figure 3; (9)); exon skipping, 5ʼ alternative splice site, 3ʼ alternative
splice site, mutually exclusive exons, and intron retention. Intron retention usually
introduces a pre-mature stop codon, resulting in the formation of truncated proteins or
targeting the transcript for degradation by nonsense-mediated decay, the process by
which mRNA containing premature stop codons are recognized and degraded (10).
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Figure 1. Location and components of the E complex bound to pre-mRNA.
The branch point is bound by SF1/BBP, and U2AF, the subunit U2AF65 binds to
SF1/BBP along with the other U2AF subunit, U2AF35, which binds to the 3ʼ splice site.
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Figure 2. Spliceosomal components during phases of the splicing reaction.

The dynamic rearrangement of spliceosomal subunits is critical for intron-exon
recognition, catalytic activation, and subsequent ligation of the exon-exon product.
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Alternate splice site selection can be influenced by a variety of factors, whether
those be cis-acting or trans-acting elements or an environmental stimulus. Alternative
splicing can lead to different isoforms of the same protein, or form an entirely new
protein.
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III. Functional Consequences
a. Tissue specific
Within an organism, there are proteins comprised from different splice variants
depending on the tissue type. Tissue specific isoforms make up 10-30% of all
alternatively spliced genes, and these different isoforms created by alternative splicing
allow for specificity of action and localization of the protein within the correct tissue (11).
An example of tissue specific alternative splicing is the mitochondrial phosphate
transporter gene SLC25A3. Exons 3A and 3B of this gene are ʻmutually exclusiveʼ
meaning that one or the other is included, but not both. This kind of splicing, termed
ʻswitch-likeʼ, results in exons that are normally recognized as exons in one tissue being
recognized as introns in another tissue. In an mRNA-seq study, exon 3A of SLC25A3
was shown to be included in heart and skeletal muscle and 3B was seen almost
exclusively in the testes and liver (12).

b. Developmental
Muscleblind-like-1 (MBNL-1) is a protein that exhibits a developmental splicing
transition. MBNL-1 has ten coding exons, some of which are alternatively spliced (exons
3, 5, 7, 9), and the expression of these isoforms is developmentally regulated. In
humans and mice, the MBNL-1 regulatory factor controls the fetal-to-adult alternative
splicing switch by binding to YCGY sequence elements in a key set of pre-mRNAs (13).
The binding of MBNL-1 promotes either the inclusion or exclusion of alternative exons
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depending on the 3ʼ or 5ʼ placement of cis-regulatory elements within the pre-mRNA
transcript, making MBNL-1 an important regulator of splicing in development.
Over ten isoforms of MBNL-1 have been identified and are developmentally
regulated. In type 1 myotonic dystrophy the expression of MBNL-1 isoforms is altered,
which indicates a role for alternative splicing in regulating the function of the protein.
Cassette exons 5 and 7 are included mainly in fetal brain and muscle, and are
preferentially included in type 1 myotonic dystrophy patients. One hypothesis of how
type 1 myotonic dystrophy progresses, is based on a toxic RNA gain of function, which
could lead to dysregulated alternative splicing of targeted transcripts, like the insulin
receptor (INSR) gene.
In cellular models of myotonic dystrophy, mutant RNA transcripts with long-CUG
repeats form odd double-stranded RNA structures, accumulate in the nucleus, and lead
to foci that sequester ribonuclear proteins like MBNL-1 (13-16). In the instance of INSR
in myotonic dystrophy, the inactivated MBNL-1 is associated with an increase in CUGBP1, a CUG-repeat binding protein that has different specificities than MBNL-1 and a
binding site in exon 11 of INSR (17). The splicing factor hnRNP-H promotes exon
exclusion, and is also increased in myotonic dystrophy myoblasts. The combination of
the increase in amount of proteins promoting exon exclusion and the disrupted RNAprotein interaction culminate in a reduction of INSR exon 11 inclusion in models of
myotonic dystrophy (17). Additional studies have shown that there is aberrant
alternative splicing of several MBNL-1 targets in myotonic dystrophy patients and when
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MBLN1 is inactivated, suggesting a loss-of-function mechanism in myotonic dystrophy
progression (14).
c. Disease
The changes in alternative splicing documented in disease are primarily
manifested in mutations in either the cis-acting RNA elements, or the trans-acting
protein splicing factors. The cis-acting mutations disrupt regulatory RNA sequences
and affect the binding of splicing regulators. These mutations can result in the
localization of trans-acting factors to improper 5ʼ or 3ʼ splice sites, creating nonfunctional protein isoforms, premature stop codons, or out-of-frame transcripts. In some
cases, mutations in one of the splicing elements can activate the use of a cryptic splice
site, a weak splice site that is only used when a mutation occurs. Any one of these
mutations can lead to a variety of diseases including, but not limited to, cystic fibrosis,
frontotemporal dementia, Parkinsonism, retinitis pigmentosa, spinal muscular atrophy,
myotonic dystrophy, premature aging, and cancer (8).
The trans-acting mutations affect the quality or quantity of alternative or
constitutive splicing factors. System lupus erythomatosis is the classic example
associated with the splicing machinery per se. In this disease, the immune system
produces antibodies targeting to snRNPs. Autosomal dominant retinitis pigmentosa is a
disorder that eventually results in complete blindness. In this disorder, there are
mutations in the splicing factors PRPF31/U4-61k and PRP8. PRP8 is the major
enzymatic component of the spliceosome, and interacts with all spliceosomal
components (18). Many diseases involve aberrant splice site selection.
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d. Environmental stimuli
A change in splicing in response to hormones or nutrients involves activation of
signaling cascades containing kinases, which phosphorylate SR proteins.
Phosphorylated SR proteins are active and can enter the nucleus to bind to pre-mRNAs
and influence splice site selection. The hormone, insulin and the nutrient, arachidonic
acid have been shown to regulate amount of glucose-6-phosphate dehydrogenase in
opposite ways. Treatment of primary rat hepatocytes with insulin increases the
phosphorylation of SR proteins, while treatment with arachidonic acid decreases the
phosphorylation of SR proteins in the liver (19). Treatment of hepatocytes or liver with
insulin/refeeding results in an increase in the spliced form and amount of G6PD, while
arachidonic acid/starvation results in a decrease in the spliced product and amount of
G6PD mRNA (20). In hepatocytes and whole liver, SR proteins have been shown to
bind to a splicing enhancer element within exon 12 of G6PD.
Another example of regulated splicing by insulin involves an isoform of protein
kinase C (PKC), protein kinase CβII (PKCβII). The Cooper lab has shown that Akt2
stimulation by insulin promotes βII exon inclusion through the phosphorylation of SRp40
(21). Binding of SRp40 introduces a stop codon within the βII exon, resulting in a
truncated isoform of PKC. The insulin regulation of PKCβII has been shown in several
cell types including: primary rat hepatocytes, 3T3-L1 adipocytes, HepG2 cells, and L6
cells. There are two alternative sites that allow for inclusion of the βII exon, one is
directly at the 5ʼ splice site (I), and the other is a little farther downstream of the 5ʼ splice
site, in the intron (II). The regulation of splice site selection in insulin sensitive tissues
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has been shown to vary in splice site selection (I vs. II) and amount of time after insulin
treatment to the increase in isoform PKCβII (22). The different cellular responses to
insulin stimulation show splice site preference and temporal regulation depending on the
context and cellular uses for insulin. The examples of nutrient and hormonal regulation
of metabolic genes suggest that SR proteins are directly involved in mediating the
changes in splicing in metabolic tissues, making them prime candidates for the
regulation of other lipogenic genes in the liver.

IV. Molecular Mechanisms
Alternative splicing is controlled by targeted sequences within the pre-mRNA
known as cis-acting elements, and complexes of proteins and ribonuclear proteins
known as trans-acting factors. Many of the cis-acting elements contain additional
information in the form of 6-8 nucleotide sequences known as splicing enhancers or
silencers. These elements within the pre-mRNA serve to recruit trans-acting splicing
factors that can activate or suppress splice site selection as well as spliceosomal
formation (9; 23).
The cis-acting elements bind splicing enhancers like SR proteins when the
sequence is an enhancer element, or splicing silencers, like heterogeneous ribonuclear
particles (hnRNPs), in the case of a silencing element. These binding sequences were
determined using SELEX (systematic evolution of ligands by exponential enrichment)
and were shown to have a high degree of degeneracy, meaning a single factor can
regulate a large number of genes by binding to more than one sequence (24). Further
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more, because SELEX is an in vitro technique, these results do not prove that the
sequence has biological activity. The variation in mRNA binding sequences leads to the
question of whether the sequences alone determine SR protein/hnRNP binding, or if
other trans-acting factors or RNA secondary structures contribute to SR protein/hnRNP
association with mRNA.

a. Splicing enhancers
SR proteins are a family of at least seven RNA binding proteins
(SF2/ASF, SC35, 9G8, SRp20, SRp40, SRp55, and SRp75). They bind to sequences
within the pre-mRNA known as exonic splicing enhancers (ESEs)). Bound SR proteins
block the binding of other regulatory proteins, like hnRNPs that may favor exon
exclusion, while the SR proteins themselves promote exon inclusion. SR proteins bind
to the RNA using a RNA recognition motif (RRM) at their N-terminus that determines
RNA-binding specificity. Their C-terminal RS domain facilitates protein-protein
interactions and recruitment of the spliceosomal components (Figure 4, (25; 26)). SR
proteins effectively promote spliceosome assembly on nascent pre-mRNAs to catalyze
intron removal during the processing of actively transcribed genes. The RS domain can
also contact the pre-mRNA directly via the branch point and the 5ʼ ss, which may
indicate another method of spliceosomal assembly.
There are two main models proposed for how SR proteins direct exon inclusion.
The recruitment model proposes that bound SR proteins can recruit and stabilize
interactions between the U1 snRNP at the 5ʼ ss and U2AF65 and the 3ʼ ss. The other
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model proposes that SR proteins form a network of protein-protein interactions across
introns to connect the 5ʼ and 3ʼ ss early in spliceosomal assembly, as shown by the
interaction of SF2/ASF and SC35 with U1-70K at the 5ʼ ss and with U2AF at the 3ʼ
splice site in an RS domain-dependent manner (25). SR proteins may facilitate the
recruitment of the U4/U6, U5 tri-snRNP to the inactive spliceosome through other SRrelated proteins.
The main mode of SR protein regulation is reversible phosphorylation of the RS
domain. This serine-arginine rich domain is extensively phosphorylated on serine
residues and plays an important role in regulating the localization and activity of SR
proteins. For example, phosphorylation of SF2/ASF enhances protein-protein
interactions with other RS domain-containing splicing factors, like U1-70K, and the
dephosphorylation of all SR proteins is required for splicing catalysis to proceed (27;
28). There are several protein kinase families that phosphorylate the RS domain of SR
proteins, the SR protein kinase (SRPK) family, the Clk/Sty family of dual specificity
kinases, Akt, and topoisomerase I (25). These kinases are required for SR protein
activation and the majority of their functional ability.
SR proteins are localized in the nucleus, specifically in the nuclear speckles.
When the SR proteins are hyperphosphorylated, they move out of the nuclear speckles
and are recruited to sites of RNA polymerase II (RNAPII) transcription where at least
some bind to the CTD (29).
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Figure 4. Structural and functional domains of serine-argnine (SR) proteins (25).
The RRM is the RNA-recognition motif, while the RS is the serine-arginine repeat
domain. Some of the SR proteins also have a second RNA binding domain known as
the RNA-recognition motif homology domain (RRMH).
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The binding of SR proteins to RNAPII and the pre-mRNA can occur co-transcriptionally
(30). Localization on the CTD allows binding to ESEs coincident with transcription. In
addition to shuttling to and from nuclear speckles, the SR protein family members, with
the exception of SC-35, have been shown to shuttle between the nucleus and the
cytoplasm.
The shuttling activity suggests a role in transporting mRNA out of the nucleus
(31), and the splicing factors SRp20, 9G8, and SF2/ASF have been shown to interact
with the mRNA nuclear export receptor TAP/NFX1 with a higher affinity when
hypophosphorylated, linking mRNA transport with dephosphorylation (32-34). These
studies have demonstrated the dynamic regulation of SR proteins by phosphorylation
and dephosphorylation and lead the way for studies on other posttranslational
modifications.
In mouse model systems, knockouts of SRp20, SC35, SF2/ASF all have been
shown to be embryonic lethal. The lethality of knocking out these splicing factors
indicates the diversity of their functions and necessity for sustaining cellular viability.

b. Splicing inhibitors
hnRNPs bind to exonic and intronic splicing silencer elements (ESSs and ISSs)
within the pre-mRNA. Their function has primarily been shown to be opposite of SR
proteins. They repress exon inclusion by promoting distal splice site selection, possibly
by looping out the pre-mRNA in such as way that internal 5ʼ splice sites are hidden
within the hnRNP complex.
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hnRNPs have an RNA recognition motif (RRM), that contacts the RNA using the
degenerate consensus sequences RNP-1 and RNP-2. The contact is mediated by
hydrophobic interactions between four aromatic side chains and two bases, however,
not all hnRNPs bind RNA with RRM domains. hnRNPs E/K bind RNA via the KH (K
homology) domain. This domain can only fit four bases within its narrow groove, and the
interaction with RNA is facilitated by hydrogen bonding and electrostatic interactions.
hnRNPs F/H contain qRRMs which have an extra β3ʼ loop as compared to classical
RRMs and lack the RNP consensus sequence. There are RRMs in hnRNP I, referred to
as atypical RRMs (aRRMs), that lack canonical RNP motifs (Figure 5, (35)). With the
exception of hnRNP U, all hnRNPs contain RNA-binding domains (RBDs). Splice
variants have been identified for the majority of hnRNPs and they frequently undergo
post-translational modifications. Primarily, the post-translational modifications are
phosphorylation of serine/threonine residues and methylation of arginine residues. The
function of these post-translational modifications is currently unknown. The hnRNPs
exhibit nucleoplasmic shuttling, and some do so with nuclear localization signals while
others, like hnRNPs A1 and I do so without classical nuclear localization signals (35).
As a way to identify the precise roles of hnRNPs in mRNA regulation, Konig et al.
(2010) developed a technique that provided individual-nucleotide resolution by UV
cross-linking and immunoprecipitation (iCLIP). Using this technique, hnRNPs were
found to have enhanced incorporation on silenced exons and proximal intronic regions.
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Figure 5. Structural and functional domains of hnRNPs (35).
The hnRNPs have diverse functions in the process of mRNA splicing regulation. Part of
this diversity is due to the combination of the structural and functional domains that
make up each hnRNP.
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The authors showed that hnRNPs enhance splicing when they bind in the intron
preceding the alternative exon (36). The resulting hypothesis is that hnRNPs may act as
ʻRNA nucleosomesʼ by binding the pre-mRNA, but maintain the integrity of the splice
sites and access of the splicing machinery to the pre-mRNA. Their findings suggest that
hnRNPs can serve dual purposes in splicing regulation, and their purpose depends on
the positioning of the particles on the pre-mRNA (36). The observation that hnRNPs
have a dual enhancer/repressor role adds another layer of complexity to the mechanism
of mRNA splicing.

V. SRp20
In a global analysis of the SR proteins, SRp20 and SRp75, in neural cells, a
distinct separation was made in the mRNA transcript specificity of these two SR
proteins. There was little overlap in the mRNA bound by SRp20 and SRp75, and there
were more mRNAs that were associated with, and depended on SRp20 for proper
expression (37). In neural cells, the importance of SRp20 in alternative splicing is
validated by the transcript specificity, and number of transcripts bound by SRp20.
Studies of this nature have not been attempted regarding SRp20ʼs role in regulating
splicing in the liver. There have been three SRp20 target mRNAs identified in the liver,
glucose-6-phosphate dehydrogenase (G6PD), insulin receptor (IR), and pyruvate
kinase-M (PK-M) (37-39).
SRp20 binds to exon 12 in G6PD leading to exon inclusion in the fed state. In the
fasted state, hnRNPs bind to G6PD and prevent SRp20 from binding, leading to intron
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inclusion and degradation of the transcript. G6PD is a lipogenic gene, and is
coordinately regulated with the other lipogenic genes in the liver. The binding of SRp20
to G6PD in response to nutritional status can mean that SRp20 may regulate other
lipogenic genes in a similar manner.
The splicing of IR results in two isoforms, IR-A and IR-B. The difference between
the two isoforms is a 12-amino-acid insertion in the homone-binding domain of the
receptor, which is determined by the alternative splicing of exon 11. IR-A is primarily
expressed in the embryo and lacks exon 11. This isoform promotes growth by being
able to bind insulin and insulin-like growth factor II. IR-B contains exon 11 and is
expressed in adult insulin-sensitive tissues, like the liver, muscle, and adipocytes, but
only binds insulin. The inclusion of exon 11 has been shown to be dysregulated in a
number of diseases, including type II diabetes, myotonic dystrophy, and cancer (40).
The dysreguation stems from the aberrant binding of splicing enhancers and inhibitors
to their compatible enhancer and silencer elements within alternatively spliced exon 11
and intron 10 of the human INSR gene (38). There are overlapping binding sites for
CUG-BP1, an exonic silencer and SF2/ASF, an exonic enhancer in the stem-loop
structure. There is a SRp20 binding site in the unstructured loop preceding the stemloop. Point mutations made disrupting the base pairing of the stem-loop favor exon
inclusion, while mutations that strengthen the base-pairing favor exon exclusion. The
thought is, that the binding of CUG-BP1 sequesters exon 11 within the stem-loop
excluding exon 11, while the binding of SF2/ASF and SRp20 prevent the formation of
the stem-loop, favoring exon 11 inclusion (38).
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SRp20 is involved in the splicing of another important metabolic gene, pyruvate
kinase M (PK-M). Pyruvate kinase catalyzes the last step in glycolysis, forming pyruvate
and ATP from phosphoenolpyruvate (PEP) and ADP. Exons 9 and 10 of the PK-M gene
are alternatively spliced and referred to as mutually exclusive, forming two isoforms PKM1, which includes exon 9 and PK-M2, which includes exon 10. PK-M1 is constitutively
active and present in most terminally differentiated tissues, and PK-M2 is expressed in
embryonic and undifferentiated tissues, as well as cancer cells (39). PK-M2 is
allosterically regulated by fructose-1,6-bisphosphate (FBP) and has been shown to
interact with tyrosine-phosphorylated signaling proteins. In cancer, PK-M2 is inhibited by
growth-factors, which stops flux through the glycolytic pathway, and accumulates
upstream intermediates (39). The intermediates are then shunted to anabolic pathways
and can contribute to increased cell proliferation. In an effort to understand the
mechanism of cancer growth, the features of PK-M splicing were studied.
First, Wang et al. (39) assessed the relative strength of exon 9 and 10 splice
sites, by transfecting 293 cells with mutant PK-M minigenes. The authors found that
when the 5ʼ or 3ʼ splice sites of exon 10 are inactivated, exon 9 inclusion is only
marginally rescued. When exon 9 splice sites were strengthened, a new transcript was
produced including exon 9 and exon 10. The double exon product suggests inclusion of
exon 10 is an active process and largely independent of exon 9 splicing. Next, the ciselements of PK-M were analyzed, and it was shown that exon 10 is included if placed
before exon 9, indicating that the cis-elements in exon 10 are sufficient enough to
activate exon 10 and repress exon 9 (39). The authors then analyzed the ESE
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sequences within exon 10 and found a strong SRp20 consensus sequence. Analysis of
the ESE by mutation and RBP-immunoprecipitation assay confirmed binding of SRp20
to exon 10 of PK-M, and that SRp20 binding is necessary for exon 10 inclusion.
Interestingly, overexpression of SRp20 increases exon 10 inclusion in a neuroblastoma
model preferentially including exon 9 and expressing low levels of SRp20. Also,
knockdown of SRp20 in HEK-293 cells increases lactate production and decreases
proliferation, suggesting a switch from PK-M2 to PK-M1. The discovery of another
alternatively spliced metabolic gene regulated by SRp20, in addition to G6PD and INSR,
suggests other metabolic genes may be regulated in the same fashion. Wang et al. (39)
provides more evidence of SRp20 as an oncogene by facilitating splicing that favors
increased growth and proliferation.

VI. Role of Acetylation
Splicing is coupled to transcription, and signals changing transcription rates or
chromatin structure appear to influence splice site selection. In addition, splicing factors
can be posttranslationally modified by phosphorylation, glycosylation, methylation, and
now, acetylation (2; 7; 41; 42). Thus, acetlyation of both histones and splicing factors
may be coupled to regulate gene expression.
Acetylation of the ε-amino group of lysine functions to neutralize the positive
charge carried by the nitrogen. The modification is reversible and changes the protein
function in many diverse and interesting ways. Lysine acetylation was originally
discovered as a post-translational modification of core histone tails and the extent of
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acetylation is regulated by histone acetyltransferases (HATs) or histone deacetylases
(HDACs) (43). The first evidence of SR proteins being directly acetylated comes from
Edmond et al. (3), who identified SC35 as being a target of Tip60. Tip60 is the catalytic
subunit of the NuA4 histone acetyltransferase complex, and has shown to be involved in
DNA damage repair and transcriptional regulation. The authors showed that loss of
Tip60 increases the amount of SC35 protein and enhances the half-life of the protein.
They conclude that Tip60 regulates degradation of SC35 through a mechanism
involving the proteasomal pathway. Next, they wanted to look at what happened to
SC35 when it was deacetylated. HDAC6 is a histone deacetylase that possesses
ubiquitin-linked functions, and was chosen because of its link to the proteasome (44;
45). Overexpression of HDAC6 resulted in the accumulation of SC35 protein.
Overexpression of Tip60 significantly reduced SC35 phosphorylation, while the
knockdown of Tip60 enhanced SC35 phosphorylation. The results suggest interplay
between Tip60 negatively regulating SC35 phosphorylation to control SC35 protein
activity.

VII. Histone Modifications in Alternative Splicing
Histone modifications determine the availability of DNA to be replicated, transcribed into
mRNA, and translated into protein. Recent observations along sites of histone
modifications include; the presence of cotranscriptional pre-mRNA splicing, alternative
splice site choice influenced by RNA polymerase II elongation rate, the presence of
chromatin remodelers, and lysine deacetylase (KDAC) activity (30; 46; 47).
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Fibroblast growth factor receptor 2 (FGFR2) is a receptor tyrosine kinase gene
with an established alternative-splicing pattern where exons IIIb and IIIc undergo
mutually exclusive and tissue-specific alternative splicing. Studies have shown that exon
IIIb is preferentially included in epithelial cell types and IIIc is included in mesenchymal
cell types. The switch from one cell type to another is nearly perfect in models of
epithelial-to-mesenchymal transition (EMT), linking the switch to metastatic, highly
invasive cancers (48). In the prostate, exon IIIb is included, while in human
mesenchmyal stem cells, exon IIIc is included. Exon choice was found to be regulated
by polypyrimidine-tract binding protein (PTB) binding to silencing elements around exon
IIIb. This phenomenon was mapped by qChIP and identified the histone modifications in
the alternatively spliced regions of FGFR2 Overexpression of the H3-K4 methylase
increased the usage of the normally excluded PTB-dependent exon, and not of PTBindependent exons or constitutively spliced exons. These findings demonstrated that
histone modifications can influence alternative splicing (4).
Histone acetlyation is classically linked to an increase in gene activity. In cancer
models, treating HepG2 and Huh6 cells with HDAC inhibitors like suberoylanilide
hydroxamic acid (SAHA), has been effective in activating the extrinsic apoptotic
pathway, increasing the expression of FasL, FasL receptor, and activating caspase-8
(49). SAHA enhanced the level of Bim proteins, stimulated the alternative splicing of
Bcl-X to its proapoptotic form, Bcl-Xs, induced degradation of Bid into the apoptotic
factor t-Bid, and dephosphorylated Akt. These effects were seen in the transformed cell
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lines, HepG2 and Huh6, but not in primary human hepatocytes (PHH), indicating a
potential role of HDAC inhibitors for treatment in liver cancer.

VIII. Acetylation and metabolism
ATP-citrate lyase provides acetyl groups for histone acetlyation through citratederived acetyl CoA. Silencing ATP-citrate lyase with siRNA decreased the amount of
histone acetlyation for all core histones (50). Histone acetlyation was rescued with
supraphysiologic levels of acetate, the substrate used by acetyl CoA synthetase, and
occurred in a dose-dependent manner. Upon ATP-citrate lyase silencing the expression
of Glut4, hexokinase 2, phosphofructokinase-1, and lactate dehydrogenase A, along
with a gene involved in fatty acid synthesis, carbohydrate responsive element-building
protein (ChREBP) were suppressed and then able to be rescued by acetate. The
transcriptional effects correlated well with the glycolytic activity with a reduction of 32%
in glucose consumption (50).
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CHAPTER 2
MATERIALS AND METHODS
Cell Culture
The human hepatocarcinoma cell line, HepG2, was used to study the effect of
acetylation and alternative splicing. The cells were plated and cultured in Dulbeccoʼs
Modified Eagleʼs Medium (GIBCO®) with 10% FBS (Atlanta Biologicals) and 1%
antibiotic-antimycotic (GIBCO®). When confluent, the cells were passaged at a 1:3 or
1:4 ratio. The media was changed every 2-3 days.

Western Blot Analysis
Western blot analysis was done as described in Walsh et al. submitted.
Acetylated proteins were detected using a polyclonal acetyl-lysine antibody (Cell
Signaling). The PVDF membrane was incubated overnight in polyclonal rabbit acetyllysine IgG antibody diluted 1:1000 in 5% bovine serum albumin (BSA). The antibody
was synthesized by (Cell Signaling Technology®). The membrane was incubated in a
goat anti-rabbit secondary antibody (Zymed®) diluted 1:2000 in 5% non-fat dry milk.
After washing in TBS-T, antibody bound acetyl-lysine was visualized using ECL-Plus™
(General Electric Healthcare®). Chemi-fluorescent signals were detected by X-ray film
or by the Typhoon scanner using ImageQuant™ software.
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RT-PCR arrays
Total RNA was isolated from the DMSO, SAHA, and MS-275 treated HepG2
cells after 16 hours. The RNA was reverse transcribed (RT) in 200μl reactions
containing 10μg of RNA per reaction. Table 1 shows the components of the RT reaction
and the PCR parameters. The cDNA was amplified using primer sets for 84 different
alternatively spliced genes developed by the Stoilov lab using 96 or 364 well plates. The
cDNA was subjected to acrylamide-urea electrophoresis (7.5M urea, 6% acrylamide,
10X Tris/Borate/EDTA (TBE)) in large sequencing gel apparatuses and visualized on
the Typhoon phosphoimager (See Appendix I for gel-setup). Quantitation of spliced
products was done using the ImageQuant software.
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CHAPTER 3
ACETYLATION AND ALTERNATIVE SPLICING

Introduction
Acetylation has primarily been associated with regulation of histone function and
chromatin structure. Until recently, the fields of chromatin biology and pre-mRNA
splicing were thought to be completely independent of one another. More recent studies
have shown that the two fields are intimately connected by demonstrating that DNA
associated with nucleosomes is preferentially located in exons, and that the SR
proteins, SRp20 and ASF/SF2 bind to the tail of histone H3 to control cell cycle
progression (51; 52). The observation of SR proteins associated with chromatin
suggests the SR proteins may undergo some of the same reversible posttranslational
modifications that histones do, like acetylation. Lysine acetylation is a highly regulated
process that is directed by the opposite actions of histone acetyltransferases (HATs)
and histone/lysine deacetylases (HDACs or KDACs).
A proteomics study by Choudhary et al. (2) identified many new proteins as
targets for lysine acetylation, including SR proteins. Adding an acetyl-group to a lysine
neutralizes the positive charge and can change the structure and function of the
modified target protein, making acetylation of SR proteins a worthwhile topic to study.
The function and location of acetylation of SR proteins has not been identified, but the
RRM domain is lysine rich and a candidate region. If acetylation of SR proteins has any
functional relevance, then there is potential for alternative splicing to be altered as a
result. The Choudhary et al. (2) study examined acetylated targets in MV4-II, Jurkat,
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and A549 cells, all myeloid adenocarcinoma cell lines. We sought to determine if
acetylation of SR proteins could occur in liver cells and if this regulated alternative
splicing. The first step was to identify if HDAC inhibition has an effect on alternative
splicing.

Results
Acetylation of SR proteins has been detected in cancer cell lines, and due to our
interest in the liver, HepG2 cells were chosen as the primary model for our
investigations. The cells are derived from a human hepatoma, and the use of human
cells permitted the use of the PCR arrays developed by Peter Stoilov to detect cancer
specific alternative splicing events. These arrays contained primer sets that amplified
the RNA products of 84 genes and permitted detection of the alternatively spliced
isoforms of their mRNAs. Modification of these arrays for use in primary rat hepatocytes
would be difficult and time consuming. The primary rat hepatocytes are also sensitive,
are only viable for 5 days in culture before de-differentiating, and may not withstand
treatment with HDAC inhibitors.
Cell lysates from HepG2 cells incubated with 2 μM SAHA or 5 μM MS-275 for 16
hours were subjected to western blotting with an anti-acetyl lysine antibody to detect
changes in acetylation (Figure 6). HDAC inhibition resulted in an increase in acetylation
of histone H3 (H3) and histone H4 (H4) indicated by arrows (Figure 6) when compared
with DMSO.
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Figure 6. Total acetylation in HepG2 cells treated with the HDAC inhibitors
SAHA or MS-275.
Total protein was isolated from HepG2 cells at the times indicated. The left blot
shows no treatment (NA) and vehicle (DMSO) as controls compared with HepG2 cell
lysate from cells treated with HDAC inhibitors, 2μM SAHA or 5μM MS-275. The highest
acetylation was visible from histone H3 at ~17kDa and H4 at ~11kDa. MW, molecular
weight markers.
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With confirmation of the increase in acetylation, a RT-PCR screen was performed
to identify changes in splicing associated with HDAC inhibition. RNA isolated from
HepG2 cells treated with 2 μM SAHA or 5 μM MS-275 for 16 hours was reverse
transcribed, and the resulting cDNA amplified using the PCR arrays. Several genes
exhibited changes in alternative splicing due to HDAC inhibition when compared with
the DMSO controls, as determined by visual confirmation from gel images (Appendix I;
Figure A1, A-F). Figure 7 shows a representative group of genes with no change (Figure
7A, lanes 1, 5, 9), increase (Figure 7B, lanes 5 and 9), or decrease in isoform in
response to HDAC inhibition (Figure 7B, lanes 5, 8, 9 and 12). Densitometry was
performed on the isoform bands to confirm visual changes observed in comparing the
DMSO treated and HDAC inhibitor treated groups. The raw quantification of bands using
ImageQuant software is represented in pixels per band. The subsequent normalization
of the data, by dividing pixels per band by total number of pixels in all bands per gene,
in some cases, does not match to the ratios, normalized to DMSO, or bar graph
representation (Table 1; Figure 7B, lanes 1, 5, 9, and Figure 8, RPS6KB1). The
differences from visual to numeric data may be a result of high background, lack of
product, or unequal loading of the amplified product. A solution would be to replicate the
experiment (n=3) and analyze genes listed in Table 1 again to confirm the changes in
isoform presence with HDAC inhibition.
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Figure 7. Isoform expression of genes from HepG2 cells treated with DMSO,
SAHA, or MS-275.
Total RNA extracted from HepG2 cells treated with DMSO, 2 μM SAHA, or 5 μM
MS-275 for 16 hours was reverse transcribed and the resulting cDNA was amplified with
primers designed to genes with alternatively spliced products. Each lane represents the
results from RNA isolated from 3 plates/treatment. (A) Bands with boxes are examples
of genes with no change in isoform with inhibitor treatment (lanes 1, 5, and 9). (B) Red
arrows below bands indicate an increase in isoform with inhibitor treatment (lanes 9, 5),
and blue arrows indicate a decrease in isoform with inhibitor treatment (lane 9). Refer to
Table 1 for densitometry pixel values of noted bands. Bands not referenced are misprimed products, artifacts, or primer dimers.
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The RT-PCR array showed the largest changes in decreasing isoform presence
in the genes RPS6KB1, ENAH, MKNK2, and Fas1. RPS6KB1 isoforms were generated
from regions between exon 9 and exon 10. There are two alternative exons identified by
the UCSC Genome Browser database EST collection. The inclusion of both exons
results in a product size of 441 bp. Inclusion of one exon, but not the other, results in
products with sizes of 366 bp and 188 bp. When both exons are skipped the product
size is 113 bp. Figure 8 and Table 1 show a decrease in the isoforms containing only
one of the alternative exons (366 bp or 188 bp). The splice variants detected have not
been referenced in the literature, and may be novel products induced by HDAC
inhibition.
The gene ENAH showed a decrease in expression of the 212 bp and 155 bp
isoforms with SAHA and MS-275 treatment. The decrease in the 212 bp isoform was
the most pronounced and similar with both inhibitors. The decrease in the 155 bp
isoform was not as pronounced with SAHA treatment, as it was with MS-275 treatment
(Figure 8, ENAH). The literature suggests that the amplified isoforms correspond to the
cassette exons 3a and 3b, also known as INV (+++) and (++), respectively (53).
There were two isoform changes associated with the gene MKNK2. In response
to SAHA treatment there was a decrease in the expression of a 193 bp isoform and an
increase in the expression of a 170 bp isoform. The 193 bp isoform is associated with
MKNK2a, and the 170 bp isoform is associated with MKNK2b (Table 1, Figure 8,
MKNK2).
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Expression of the 130bp isoform of Fas1 decreased with SAHA and MS-275
treatment (Figure 8, Fas1). This isoform represents a decrease in the exon 6 deletion
isoform of Fas1 with HDAC inhibition.
The largest increase in isoform appearance with HDAC inhibition was in the 156
bp product of PTK2 (FAK) (Table 1, Figure 8, PTK2) This area corresponds to an
increase in the inclusion of exon 31, an exon not normally found in FAK transcripts.
Based upon the data generated from the RT-PCR arrays, genes represented in
the literature with identifiable changes in isoform presence comparing DMSO to HDAC
inhibitor treated groups were; PTK2, ENAH (hMENA), MKNK2, and Fas1. Genes with
stars in Table 1 also show changes in splicing with HDAC inhibition and warrant further
investigation by qRT-PCR.
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Figure 8. Changes in isoform abundance of genes in HepG2 cells treated with
SAHA or MS-275 from Table 1.
Changes in alternative splicing were assessed as in Figure 7. The pixel density
of the isoform bands was quantified using the ImageQuant software for the Typhoon
imager. Values from Table 1 were used to populate the bars on the graph. The bars
represent pixels per band/pixels of total # of bands per gene normalized to DMSO with a
log2 transformation (y-axis). Each bar represents the results from RNA isolated from 3
plates/treatment. The blue bars represent change in isoform presence with SAHA
treatment, relative to DMSO treatment. Red bars represent isoform presence with MS275 treatment relative to DMSO treatment.
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Table 1. Quantification of isoform expression in HepG2 cells in response to
DMSO, SAHA, or MS-275 treatment.
*Genes showing changes with HDAC inhibition not described in the text.
**Alternative exon locations were determined by assembly Mar. 2006 (NCBI36/hg18)
www.genome.ucsc.edu
1

; expressed as pixels per band/pixels of total # of bands per lane

2

; log2 (SAHA1 or MS-2751/DMSO1)

Gene Name

Alternative PCR Product
Exon Type
Size (bp)

PTPRG*

CA

SCML1

CA;Alt3

MKNK2

Alt3

KAT5

BRCA1*

CA

Alt5

FGFR2

ME;ME

ENAH

CA;CA

CASK*

DMSO 1

SAHA 1

Log 2,
Log 2,
Chomosome
MS-275 1 SAHA/DMSO2 MS-275/DMSO 2
#

257

0.143

0.105

0.127

1.66

1.85

170

0.857

0.895

0.873

2.06

2.03

0.828

0.825

0

1.99

0

0
0.171

0
0.175

0
0

0
2.03

0
0

~193

0.372

0.189

0

1.42

0

~170

0.628

0.811

0

2.45

0

191
194
274
278

330

0.112

0.139

0.100

2.36

1.85

174

0.888

0.861

0.900

1.96

2.02

179
126

0.787
0.213

0.853
0.147

0.813
0.187

2.12
1.61

2.05
1.84

165

0.377

0.343

0

1.88

0.00

126

0.623

0.657

0

2.08

0.00

224

0

0.0865

0

0.00

0.00

212

0.0641

0.0135

0.01873

1.16

1.22

167
155

0.8421
0.0937

0.8212
0.0787

0.93281
0.04846

1.97
1.79

2.16
1.43

CA;CA

283
245
212
177

0.1131
0.0931
0.7506
0.0431

0.1142
0.1122
0.7052
0.0684

0.116
0.15
0.6754
0.05828

2.01
2.30
1.92
3.01

LRRFIP2

CA

311
239

0.5077
0.4923

0.5703
0.4297

0.5749
0.4251

ECT2*

CA

275
182

0.0697
0.9304

0.0821
0.9179

0.1039
0.8961

MAX

CA

PTK2
Fas1

Alt. Exon Location**

Chr3

62191939-62192025

ChrX

17673497-17673580

Chr19

1988667-1990737

Chr11

65237395-65237550

Chr17

38496978-38,500,286

Chr10

123314942-123315208;
123314006-123314083

Chr1

223,789,832-223,789,888;
223,785,371-223,785,382

2.04
3.05
1.87
2.55

ChrX

41299797-41299832;
41301229-41301297

2.18
1.83

2.19
1.82

Ch3

37107962-37108033

2.26
1.98

2.81
1.95

Chr3

173955967-173956059

259

0

0

0

0.00

0.00

158

1

0.9982

0.9977

2.00

2.00

CA

156
147

0.006
0.994

0.0057
0.9943

0.01178
0.98822

1.94
2.00

3.93
1.99

Chr8

141748981-141748989

CA

193
130

0.967
0.033

0.982
0.018

0.982
0.018

2.02
1.47

2.02
1.47

Chr10

90,760,490-90,760,552
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Chr14

64613799-64613899

Discussion
Treatment of HepG2 cells with HDAC inhibitor altered the splicing of several
genes that have diverse roles in maintaining normal cellular function (Figure 8). These
include; Fas1, PTK2 (FAK), MKNK2, and ENAH (mENA) (Figure 9). The overall
changes in splicing are small, but could be sufficient enough to significantly affect
cellular processes (Figure 8).
The HDAC inhibitors chosen for the study, SAHA (Vorinostat) and MS-275
(Entinostat) differ in their affinities for the varying HDACs and specificity. MS-275
inhibits HDAC1 (IC50 = 300nM) over HDAC3 (IC50 = 8μM), and demonstrates no
inhibitory activity to HDAC8 or HDAC6 (IC50 >100μM). SAHA inhibits Class I
deacetylases, HDAC1, HDAC2, and HDAC3, as well as, Class II deacetylase HDAC6
(IC50 < 86nM). Neither SAHA nor MS-275 inhibit the Class III HDACs, also known as
sirtuins (SIRT1-7). Class I HDACs have one catalytic site, while Class II HDACs have
two catalytic sites. Both classes of HDACs are zinc-dependent enzymes. The
differences in affinity and specificity of the HDAC inhibitors may explain the change in
splicing; by ruling out deacetylases based on comparing the altered splicing pattern
between SAHA and MS-275 treated groups.
The two inhibitors chosen have been studied in depth and are either in use for
the treatment of cancer, in the case of SAHA (Vorinostat), or in clinical trials. MS-275
(Entinostat) is in many phase II clinical trials in the treatment of breast and lung cancers.
SAHA, now more commonly known as Zolinza, is used in the treatment of cutaneous Tcell lymphoma that has gotten worse, not responded to treatment, or recurred after
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taking other medications. Normal cells are relatively resistant to HDAC inhibitor induced
cell death, perhaps because normal cells have regulatory mechanisms in place that
prevent HDACs from deacetylating inappropriate substrates (49).
The change in expression of Fas receptor isoforms is an example of an effect of
HDAC inhibition that may have functional consequences. The bands represent the
presence of exon 6 or absence of exon 6. In cancers, the Fas receptor is a way for
tumor cells to evade detection by the immune system. Normally, Fas is expressed on
the cell surface, and when bound to Fas ligand on cells can initiate a signaling cascade
leading to cell death. The alternative splicing of Fas, leads to the deletion of exon 6,
eliminating the transmembrane domain, and leading to an unbound souble Fas (Figure
9A). The soluble Fas is thought to inhibit Fas-mediated cell death by binding Fas ligand
before it can recognize membrane bound Fas. In light of this, we see a decrease in
exon 6 exclusion with HDAC inhibitor treatment, which indicates that more exon 6
included transcripts present in the cells treated with HDAC inhibitors (Figure 8, (48)).
The HDAC inhibitors appear to be increasing the presence of membrane bound Fas,
which would lead to cell death, and is advantageous in a cancer model.
MAP kinase interacting serine/threonine kinase 2 (MKNK2) is another RNA
whose splicing may have functional significance. The activation of MKNK2 by Erk or
p38 MAP kinase α/β allows it to interact with the scaffold protein eIF4G and
phosphorylate eIF4E. eIF4E is responsible for binding to the 5ʼ cap of mRNA and is part
of the pre-initiation complex regulating translation. The different splice variants of
MKNK2 are the result of two alternative 3ʼ exons that encode proteins with the same N-
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terminal and catalytic domain, but vary at their extreme C-termini (54). MKNK2a uses
the first 3ʼ-splice site while MKNK2b utilizes the second, which eliminates the MAPK
binding domain (Figure 9B). MKNK2b is localized in the cytoplasm and nucleus, while
MKNK2a is primarily cytoplasmic. MKNK2b has been shown to bind to the estrogen
receptor β and associates with promyelocytic leukemia protein (PML). PML has been
shown to bind eIF4E and decrease its affinity for capped mRNA, impairing translation.
The association of MKNK2b with PML may cooperate in restricting the transport of
cancer promoting (cell cycle, adhesion, motility) transcripts into the cytoplasm (54).
Alternative splicing for PTK2 (FAK) exons 13, 14, and 16 have been
characterized in the brain and are the main isoforms studied in mammalian systems
(Figure 9C, (55)). Our data shows an increase in the presence of a small 9 nucleotide
exon, exon 31, with MS-275 treatment. Exon 31 is localized immediately before the
focal adhesion-targeting domain. This exon is referred to as PWR, which corresponds to
a Pro-Trp-Arg amino acid insertion, and is in a proline rich region of FAK. FAK isoforms
containing exon 31 have been identified in mouse, but no functional mechanisms have
been identified for exon 31. A review has recently been published noting an interaction
of HEF1, ASAP1 and GRAF around this proline rich region, which calls for further
examination, as the modification of exon 31 may enhance or discourage molecular
interactions (Personal communication, Schaller lab, (56; 57)).
The alternative splicing changes of ENAH in response to HDAC inhibitor
treatment correspond to the exons known in the literature as the INV (+++) and (++)
exons. The exons, 3a and 3b, are located between the Ena/VASP homology domain
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(EVH1) and the unstructured proline rich domain of the Enah (Mena) protein. The
EVH1 domain is responsible for protein-protein interactions and the localization and
regulation of Ena/VASP. The unstructured proline rich domain interacts directly with the
actin monomer binding protein, profilin, along with G- and F-actin. The +++ and ++
exons have been shown to be included in the most invasive, metastatic cancer cells
(58). The RT-PCR array data shows a decrease in the inclusion of both exons (first set
of ENAH bars; Figure 8), but an increase in the inclusion of only the INV (+++) form
(second set of ENAH bars; Figure 8). The changes in expression are small, and need to
be confirmed by RT-PCR analysis of the exon 3a – 3b region upon HDAC inhibition. The
presence of the INV and (++) exons within the ENAH transcript have been associated
with poor prognosis in breast cancer models, due to the role ENAH plays in actin
cytoskeletal remodeling. Rapid and unchecked actin remodeling has been documented
in metastatic and aggressive cancers, leaving ENAH as an attractive target gene to
study in the context of cancer and metastasis (58).
Even the largest changes in isoform expression were small and an opposite
response was often detected using the alternative inhibitor. The lack of more or larger
responses suggest that at least in HepG2 cells, changes in the acetylation status may
not produce large effects. There are several possiblities. First, HepG2 cells are from
hepatomas and may not exhibit acetylation related regulatory events because
acetylation is already at a high level, and changes may only be seen when deacetylation
occurs. Second, the HDAC inhibitors chosen for this study differ in their binding and
specificity, which may explain opposite responses in alternative splicing. Other inhibitors
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may need to be tested to determine if there are alternative splicing differences linked to
the type of HDAC inhibitor used. This information would be valuable as HDAC inhibitors
are in use for the treatment of cancer, and many more are in clinical trials. Third, while
we saw large increases in histone acetylation, we did not determine if in fact SR
proteins were similarly affected and the experiments have not been replicated to
determine if these changes are reproducible. Fourth, a non-transformed cell type might
be appropriate for these studies, as a normal cell type control. Primary human
hepatocytes can be purchased and could be a possible model for these studies.
Overall, the changes seen in alternative splicing in genes associated with cancer
are promising. The RT-PCR array should be replicated to increase the strength of the
data, and the genes from Table 1 verified using traditional qRT-PCR.

41

Figure 9. Schematics of alternatively spliced genes with the greatest change in
isoform presence due to HDAC inhibitor treatment (55; 57-59).
Exon maps depicting the alternative exons of genes identified in the RT-PCR
array. Fas1 human gene (A); FAK and the corresponding regions in the protein affected
by exon selection (B); The two isoforms of MKNK2 (Mnk2) resulting from an alternative
3ʼ splice site in exon 13. (C); The mouse mENA gene, with alternative splicing sites
marked (D). Red boxes highlight the areas exhibiting alternative splicing changes with
HDAC inhibitor treatment.
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APPENDIX I

Table A1. List of genes included in the RT-PCR array.
The genes included in the array were chosen for their involvement in cancer and
tumor formation; including but not limited to vascularization, metabolism, cell motility,
and gene regulation.
Gene
AFF3
AKAP1
AKAP8L
ANXA7
APC
ASPH
BCL2L1
Bin1
BRCA1
CASC4
CASK
CASP1
CCND1
CD44
CDH1
CEACAM1
CLK1
CNNM2
CTNNB1
CYFIP2
ECT2
EHBP1
EIF2AK4
EIF4A2
EMP3
ENAH
EXOC1
Fas
FGFR1
FGFR2
FN1_EDA
FN1_EDB
Fyn
Gli1
HYAL2
IL-6
IL-10

Gene
IL-15
IL-18
IL-24
IL-25
INSR
KAT5
KIF23
LDHC
LRRFIP1
LRRFIP2

Gene Name
AF4/FMR2 family, member 3
A kinase (PRKA) anchor protein
A kinase (PRKA) anchor protein 8-like
annexin A5
adenomatous polyposis coli
Aspartate beta-hydroxylase
BCL-xS, BCL-xL
bridging integrator 1
breast cancer 1, early onset
cancer susceptibility candidate 4
calcium/calmodulin-dependent serine protein kinase
(MAGUK family
caspase 1, apoptosis-related cysteine peptidase
cyclin D1
CD44 molecule
cadherin, E-cadherin
carcinoembryonic antigen-related cell adhesion
molecule 1
CDC-like kinase 1 (CLK/STY)
Cyclin M2
catenin (cadherin-associated protein) beta 1
cytoplasmic FMR1 interacting protein 2!
epithelial cell transforming sequence 2 oncogene
EH domain binding protein 1
eukaryotic translation initiation factor 2 alpha kinase
4, GCN2
eukaryotic translation initiation factor 4A2
epithelial membrane protein 3
enabled homolog (Drosophila)
exocyst complex component 1
TNF receptor superfamily, member 6
fibroblast growth factor receptor 1
fibroblast growth factor receptor 2
fibronectin 1 eda exon
fibronectin 1 edb exon
FYN oncogene related to SRC, FGR, YES
glioma-associated oncogene family zinc finger 1
hyaluronoglucosaminidase 2
interleukin 6
interleukin 10

MAGI1
MAPK10
Max
MKNK2
MLX
MST1R
MYO18A
MYO9A
PAX3
PKM2
PTPRG
PTPRS
PTK2
PTK2B
Rac1
RBM5
RPS6KB1
RPS6KB2
SCML1
SOX6
Syk
SYNE2
TERF1
TIAM2
TPD52
TPD52L1
VEGF
WAC
ZEB2
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Gene Name
interleukin 15
interleukin 18 (interferon-gamma0inducing factor)
interleukin 24
interleukin 25
insulin receptor
lysine acetyltransferase 5
kinesin family member 23
lactate dehydrogenase C
leucine rich repeat (in FLII) interacting protein 1
leucine rich repeat (in FLII) interacting protein 2
membrane associated guanylate kinase, WW and
PDZ containing 1
mitogen-activated protein kinase 10
MYC associated factor X
MAP kinase interacting serine/threonine kinase 2
MAX-like protein X
macrophase stimulating 1 receptor (c-met-related
tyosine kinase)
myosin XVIIIA
myosin IXA
paired box 3
pyruvate kinase, muscle
protein tyrosine phosphatase, receptor type G
protein tyrosine phosphatase, receptor type S
protein tyrosine kinase 2
protein tyrosine kinase 2 beta
ras-related C3 botulinum toxin substrate 1 (rho
family, small GTP binding protein)
RNA binding motif protein 5
ribosomal protein S6 kinase, 70kDa, polypeptide 1
ribosomal protein S6 kinase, 70kDa, polypeptide 2
sex comb on midleg-like 1
SRY (sex determining region Y) - box 6
spleen tyrosine kinase
spectrin repeat containing, nuclear envelope 2
telomeric repeat binding factor (NIMA-interacting) 1
T-cell lyphoma invasion and metastasis 2
tumor protein D52
tumor protein D52-like 1
vascular endothelial growth factor
WW domain containing adaptor with coiled-coil
zinc finger E-box binding homeobox 2
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Figure A1. Gene products from primers targeting alternative exons in HepG2

cells treated with DMSO, SAHA, or MS-275.
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APPENDIX II
IDENTIFICATION OF NOVEL RNA TRANSCRIPTS REGULATED BY
SRp20
Specific Aim #2:
*The identification of transcripts regulated by SRp20 in the liver is an ongoing specific
aim in the lab.
Hypothesis
Increase in SRp20 activity will affect other lipogenic genes in the liver, providing
means for dysregulation of gene expression and/or alternative splicing. These changes
could potentiate the use of pathways involved in growth, differentiation, motility, and
tumorigenesis in hepatocytes, which could lead to the formation of hepatomas.
Identification of novel RNA transcripts regulated by SRp20
Primary rat hepatocytes will be infected with an adenovirus expressing SRp20.
RNA extracted from these and control hepatocytes infected with empty adenovirus will
be used to probe Affymetrix splice-junction arrays. The data obtained will be screened
for transcripts altered by the overexpression of SRp20. Pathways increased or
decreased by overexpression of SRp20 will be identified and the cause of these
changes, alternative splicing or overall expression of existing isoforms will be further
studied.
Introduction
Glucose 6-phosphate dehydrogenase (G6PD), a nutrient responsive gene in the
liver, has been shown to have an ESE element within exon 12 (3). The ESE is bound by
SRp20 and this binding is regulated by nutritional status (Suchanek, unpublished). In
addition to changes in binding activity, the phosphorylation of SRp20 is also regulated.
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Insulin increases and arachidonic acid decreases SRp20 phosphorylation in primary rat
hepatocytes. Little is known about other targets of SRp20 in liver and if it plays a larger
role in the regulation of alternative splicing by nutritional status. Increases in SRp20
amount are also observed in ovarian and cervical tumors, as well as in hepatomas (45;
46, Cyphert and Salati, unpublished). The effect of SRp20 overexpression on gene
expression and isoform switching in primary rat hepatocytes will be evaluated by the
lab.
Progress
The construct for SRp20 overexpression has been successfully cloned into the
pacAd5-NpA-CMVK adenoviral vector by Amanda Suchanek. The pacAd5-CMVKFLAG-SRp20 construct was transfected into HEK 293 cells, the virus released, and
amplified.

Adenoviral Materials and Methods:
Subcloning Strategy For PacAd5-FLAG-SRp20 (developed by Amanda Suchanek)
The FLAG-SRp20 construct in pCS2 was a generous gift from the Roz SandriGolden lab. The adenoviral vector (pacAd5-CMVK) and vector-containing insert (pCS2FLAG-SRp20) were digested with XbaI and XhoI to linearize the DNA. The DNA was
cleaned up using QIagen Gel Extraction Kit modified protocol for reaction cleanup. The
vector and insert were then treated with Klenow to create blunted ends. The Klenow
reactions were cleaned up using the Qiagen Gel Extraction Kit reaction cleanup
protocol. The blunted vector and insert were digested with BamHI, and run on an 0.7%
agarose gel to isolate desired fragments. Removal of agarose and purification of vector
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and insert DNA was done with the Qiagen Gel Extraction Kit and eluted in EB. Next, the
vector was phosphatase treated and inactivated to prepare for ligation.

Ligation calculations:
25ng vector x 0.950kb insert
6.2kb vector

= 3.8 x ratio of insert to vector (e.g. 3:1, 5:1, 8:1)

The ratio chosen was 8:1 insert to vector, respectively. The ligation reactions were run
overnight at room temperature. The next day, 5μl of the ligation reaction was
electroporated into ~40μl of XL1-Blue electro-competent E.coli in 0.2μm-gap cuvettes.
The pulse controller was set at 2.5kV, 25μF capacitor, 200Ω pulse control. Next, a pulse
was delivered to each sample, and 950μl of Super Optimal broth with Catabolite
repression (SOC) was immediately added to each cuvette and transferred to 1.5mL
eppendorf tubes. The tubes were incubated at 37°C for 1 hour and 100μl of each plated
onto LB/Amp100 plates to grow overnight in a 37°C incubator. The colonies of the 8:1
ligation were selected, grown-up and checked for presence of insert by enzymatic
digestion and sequencing.

Cell Culture Conditions
Transfection, Purification, and Titer of PacAd5-FLAG-SRp20
The pacAd5-CMVK-FLAG-SRp20 plasmid was transfected into 70-80% confluent
293 cells with FuGENE 6 Transfection Reagent (Roche Applied Science). First, 16-24
hours before transfection, 2X106 cells were plated on 60mm dishes in antibiotic free
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MEM medium. Next, to prepare the DNAs for transfection, the pacAd 9.2-100 backbone,
pacAd-GFP, and the pacAd5-CMVK-FLAG-SRp20 plasmid were digested with PacI to
linearize the DNAs. The cut pacAd5-CMVK-FLAG-SRp20 and pacAd-GFP were
cleaned-up using the Qiagen Reaction Clean-Up kit, while the pacAd 9.2-100 backbone
had to be phenol-chloroform extracted due to its large size of 34.9kb. All DNAs were
eluted in ddH2O and stored at -20°C.
To prepare the transfection reagents, 9μl of FuGENE6 was added to 97μl of
serum-free, antibiotic free MEM media for each DNA, and incubated at room
temperature for 5 minutes. Next, the DNAs for transfection were added to the medium
and transfection reagent. As instructed by the Cell Bio Labs© protocol, 4μg of pacADCMVK-FLAG-SRp20 and 1μg of pacAd 9.2-100 backbone were added to one tube and
4μg of pacAd5-GFP and 1μg of pacAd 9.2-100 backbone added to another. The
mixtures were incubated for 20 minutes at room temperature and applied dropwise to
293 cells with swirling for complete coverage of the cells. After 24 hours the medium
was aspirated amplified in 293 cells, and the virus purified using the ViraBind™
purification kit (Cell Bio Labs). . Briefly, the media containing the viral particles will be
passed over a purification filter, washed twice, and eluted. Next, the virus will be titered
using the QuickTiter™ adenovirus titer immunoassay kit (Cell Bio Labs). The titers are
determined by preparing serial dilutions of adenovirus from 10-3 to 10-7, infecting the 293
cells for 2 days, fixing them with methanol, and incubated with an anti-Hexon primary
antibody, followed by incubation with a HRP-conjugated secondary antibody. The virus
will be visualized using 3,3´-diaminodbenzidine (DAB), and the cells will be a dark
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brown color if infected with adenovirus. The titer will be calculated by counting the
infected cells on a hemacytometer using the formula for a 12-well plate.

Equation 1: Viral Titer (ifu/mL) = (average positive cells/field) x (150 fields/well) x
(dilution factor)
(0.1mL)

Primary Rat Hepatocyte Isolation and Culturing
Hepatocytes will be isolated from male Sprague-Dawley rats as previously
described (20). Briefly, rats are anesthetized using Isoflurane and a catheter is inserted
into the inferior portal vein to deliver calcium-free buffer (0.14 M NaCl, 6.7 mM KCl, 0.02
M HEPES, pH 7.4, 25mM glucose, 250 μM EGTA) at 40ml/min followed by 100ml of
collagenase buffer (67 mM NaCL, 6.7 mM KCl, 0.1 M HEPES, pH 7.4, 6 mM CaCl2 *
2H2O, 25 mM glucose, 1mg/ml collagenase H, 0.05 mg/ml trypsin inhibitor). Following
collagenase treatment, the liver will be removed, combined with Waymouthʼs medium
supplemented with 20 mM Hepes, 0.5 mM serine, 0.5 mM alanine, penicillin (100
μg/ml), streptomycin (100 μg/ml), gentamicin (50 mg/ml), and bovine serum albumin
(BSA), and filtered through a nylon mesh. Cells will be counted and plated at 8 x 106
cells per 60mm collagen coated plate in Waymouthʼs medium supplemented with BSA
and newborn calf serum (NCS). After 24 hours the media will be changed, and the
hepatocytes infected with adenovirus for a pre-determined amount of time.
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Adenoviral Infection of 1° Rat Hepatocytes
ViraDuctin™ adenovirus transduction reagent. The reagent and adenovirus will
be added to culture medium without serum, and placed on the cells for 4 hours, then
medium containing serum will be added. The amount of time for infection of the
hepatocytes for RNA isolation will be determined by using a time course to follow the
expression of the flag tag. The time point chosen will be at an optimum overexpression
level of exogenous SRp20 as determined by Western blot analysis with a Flag specific
antibody, in addition to an SRp20 specific antibody. As a control, hepatocytes will be
infected with an adenovirus lacking the SRp20 insert. In addition, hepatocytes will be
treated with and without insulin to stimulate phosphorylation of SRp20 (Table A2).

Cell Lysate Preparation for Western Blot Analysis
Media will be aspirated from the cells and washed twice with ice-cold 1XPBS.
The cells will be incubated in 200ul of RIPA lysis buffer (150 mM NaCl, 1.0% IGEPAL®
CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) supplemented
with protease inhibitors and Benzonase nuclease (Sigma-Aldrich). The cells will be
scraped and pipetted into eppendorf tubes and subjected to sonication (15 pulses at
50% output). The cell lysates will be centrifuged at 13,000 rpm for 10 minutes and the
supernatant will be transferred to a new tube and stored at -80°. The protein
concentration of the extracts will be determined by the BCA assay (Pierce).
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Table A2. Experimental conditions for overexpression of SRp20 in primary rat
hepatocytes. Nuclear RNA will be isolated from the hepatocytes and used for
Affymetrix microarray analysis (n=3).

1° Rat Hepatocyte Treatment Groups
1

Empty adenovirus

2

Empty adenovirus + insulin

3

SRp20-Flag adenovirus

4

SRp20-Flag adenovirus + insulin
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Western Blot Analysis
Western blot analysis will be done as described in Walsh et al. submitted. SRp20
protein will be detected using a mouse anti-SRp20 antibody and an anti-FLAG antibody.
The membrane will be incubated overnight in SRp20 antibody (Invitrogen) diluted
1:5000 in 5% bovine serum albumin (BSA). The SRp20 antibody was made by injecting
a synthetic peptide corresponding to amino acids 84-104 of the human SRp20 protein
into mice. The region of SRp20 from 84-104 has yet to be resolved in a crystal structure,
but the amino acids are part of the area between the RRM and the RS domain. The
membrane will be incubated in a goat anti-mouse secondary antibody (Zymed) diluted
1:2000 in 5% non-fat dry milk. After washing in TBS-T, antibody bound SRp20 will be
visualized using ECL-Plus (GE). Chemi-fluorescent signals will be detected by X-ray
film or by the Typhoon scanner using ImageQuant software. The antibody, mAb104, will
be used to detect changes in SR-protein activity. mAb104 recognizes phosphorylated
serine residues on the SR proteins, SRp20, SRp30a/b, SRp40, SRp55, and SRp75. The
mAb104 hybridoma cell line was created by injecting mice with germinal vesicles from
Xenopus laevis (52). The mouse spleen cells were harvested and incubated with SP2/0
cells and the conditioned medium was collected after 7 days and analyzed for the
presence of antibodies. Only the conditioned medium with antibodies that recognized
lampbrush loops were selected for further characterization, because the goal was to
create antibodies to proteins associated with nascent RNA transcripts. Mouse mAb104
primary antibody will be detected with a goat anti-mouse IgM secondary antibody, and
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visualized with ECL-Plus. A proper loading control will be determined, and is likely to be
β-tubulin, lamin, or actin.

Nuclear RNA Isolation
Isolation of nuclear RNA begins with the isolation of nuclei before extracting the
RNA. Cells will be washed with 1X PBS-A, pelleted, and lysed in lysis buffer (10mM
Tris, pH 7.5, 150mM NaCl) containing 0.15% NP-40. After incubation in the lysis buffer
for 5 minutes, and sheared with a 1ml syringe to ensure complete rupture, the lysed
cells will be layered over a 24% sucrose buffer (10mM Tris, pH 7.5, 150mM NaCl) and
centrifuged at 4°C for 10 minutes at 13,0000 rpm to separate the nuclei from the other
unwanted cell matter. The nuclei will be rinsed with 1xPBS/EDTA and gently
resuspended in a 50% glycerol buffer (20mM Tris, pH 7.9, 75mM NaCl, 0.5mM EDTA).
Next, the nuclei will be lysed in nuclei lysis buffer (20mM HEPES, pH 7.6, 7.5mM MgCl2,
0.2,M EDTA, 0.3M NaCl, 1M urea, and 1% NP-40) and sheared with a syringe to ensure
lysis. The chromatin will be spun down at 13,000 rpm for 2 min, rinsed with
1xPBS/EDTA, and dissolved in 1ml Tri-reagent (MRC) to extract the remaining nuclear
RNA. Briefly, 100μl of 1-bromo-3-chloropropane (BCP) will be added to every 1ml Trireagent sample and mixed vigorously. After centrifuging the samples for 13,000 rpm for
15 minutes the organic phase will be transferred to a new tube and mixed with an equal
volume of isopropanol. After a 30 minute incubation on ice the samples will be
centrifuged for 8 minutes in 4°C to collect the RNA pellet. The pellet will be washed with
cold 75% ethanol, centrifuged again for 5 minutes, and resuspended in DEPC water. To
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ensure the quality of the RNA, and to remove any possible contaminating DNA, it will be
DNase treated by a 37°C incubation with TURBO DNA-free™ (Ambion), quantitated and
stored at -80°C until analysis with the Affymetrix arrays.

Microarray data analysis
Microarrays will be run and processed by Dr. Wioletta Szeszel-Fedorowicz in the
WVU Health Sciences Center Genomics Core. Raw data from the analysis will be
extracted to a text file and analyzed using the Affymetrix Power Tools (APT) and
R/Bioconductor software to detect changes in gene expression and exon splicing. APT
implements the pre-processing steps of Robust Multichip Average (RMA) and IterPLIER as well as Detection Above Background (DABG), to normalize and summarize
raw signals, as well as, to correct for the background (62). The DABG algorithm
calculates P-values for each probe set signal, which can be used to eliminate data from
filters in the following steps. Probe sets can be filtered out by variance, signal, and
Affymerix Microarray Suite (MAS), and should control for the false discovery rate (FDR)
as defined by Benjamini and Hochberg (63). The gene signals will be estimated with
APT and statistical analysis done using the Linear Model for Microarray Analysis
(LIMMA) framework in Bioconductor (64). Changes in splicing will be evaluated using
The Splice Index, which can identify new isoforms, and the GenASAP software, which
can quantify the spliced isoforms. The data can also be imported into MySQL tables to
display results and generate graphics (65).
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Real-time PCR of Candidate Genes
The amount of mRNA of candidate genes identified from the Affymetrix array will
be measured using the prepared nuclear RNA samples and real-time RT-PCR analysis
with the Qiagen Sybr Green Quantitect system as previously described (19). Ct values
obtained from each gene will be converted to ng using the standard curve established
for each primer set. Results will be expressed as a ratio to the reference gene
cyclophilin or other suitable control.
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